排名前五的靶点	数量

OXA1L(OXA1L mitochondrial inner membrane protein)	1
HDACs(组蛋白去乙酰化酶家族)	1
P-gp(P-糖蛋白-1)	1
CDT1(chromatin licensing and DNA replication factor 1)	1

关联

项与宁波大学相关的药物

AM-04(Ningbo University)

靶点-

作用机制-

在研机构

医图生科（苏州）生命科学技术有限公司 [+1]

原研机构

宁波大学

在研适应症

细菌感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Cucurbitacin IIb

靶点-

作用机制

肠道菌群调节剂

在研机构

宁波大学

原研机构

宁波大学

在研适应症

结肠炎

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Flavokawain A

靶点

CDT1

作用机制

CDT1 inhibitors

在研机构

宁波大学

原研机构

宁波大学

在研适应症

急性髓性白血病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

项与宁波大学相关的临床试验

NCT07030881

/ Not yet recruitingN/AIIT

Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy: A Multicenter Randomized Controlled Trial

This study evaluates whether adding a spacer device to triple inhaled therapy (ICS/LABA/LAMA via pMDI) can reduce acute exacerbations in elderly patients (≥65 years) with stable chronic airway diseases (COPD or asthma) who are classified as high-risk based on GOLD or GINA guidelines. High-risk is defined as ≥1 hospitalization or ≥2 moderate exacerbations in the past 12 months.
Despite receiving maximum inhaled treatment, these patients often have poor inhaler technique due to age-related limitations. A spacer may improve drug delivery, adherence, and reduce local side effects.
In this multicenter, open-label, randomized controlled trial, 380 participants will be assigned to standard therapy with or without a valved face-mask spacer. The primary outcome is the 3-month incidence of moderate-to-severe exacerbations. Secondary outcomes include lung function, adherence, inhalation technique, side effects, and patient satisfaction.

开始日期2025-06-20

申办/合作机构

宁波大学

NCT06742125

/ RecruitingN/AIIT

Drug-Coated Balloon Versus Drug-Eluting Stent in Patient With Premature ST-Segment Elevation Myocardial Infarction

The incidence of premature coronary artery disease (PCAD) is on the rise, and there is a critical need to improve long-term outcomes. Drug-coated balloon (DCB) represent a promising treatment option for patients with PCAD. However, high-quality clinical data on the impact of DCB on the long-term prognosis of myocardial infarction patients are lacking. This study aims to compare the 12-month clinical outcomes, including all-cause mortality, non-fatal myocardial infarction, and any revascularization, of DCB versus drug-eluting stent (DES) in patients with premature ST-segment elevation myocardial infarction (STEMI). The objective is to verify the efficacy and safety of the DCB implant-free regimen in these patients.

开始日期2025-05-31

申办/合作机构

浙江大学医学院附属第二医院（浙江省第二医院）

[+4]

NCT06757478

/ Not yet recruitingN/AIIT

A Clinical Study on the Combination of Mitoxantrone Liposome Injection, Bendamustine, Etoposide, and Cytarabine for Pretreatment of Autologous Hematopoietic Stem Cell Transplantation in Patients with Lymphoma

This is a single-arm, open, single-center clinical study. Patients with lymphoma who were to undergo autologous hematopoietic stem cell transplantation were pretreated with mitoxantrone hydrochloride liposome injection combined with standard doses of bendamustine, etoposide, and cytarabine before transplantation, in order to explore the safety and efficacy of this combined pretreatment regimen.
Tests were performed during the study to observe efficacy, safety, and tolerability. The treatment period was from pre-treatment to +28 days after transplantation and +28 days after stem cells were transfused. The follow-up period was followed up once a month for 6 months, every 3 months for 6 months to 2 years, and every 6 months for 2 years to 3 years after stem cell reinfusion. All subjects underwent protocol-mandated examinations during treatment to observe safety, tolerability, and efficacy.

开始日期2025-05-01

申办/合作机构

宁波大学

100 项与宁波大学相关的临床结果

登录后查看更多信息

0 项与宁波大学相关的专利（医药）

登录后查看更多信息

21,813

项与宁波大学相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Care-seeking and treatment pathways of multidrug-resistant tuberculosis patients: an analysis of real-world data from regional health information system in Ningbo City in Eastern China

Article

作者: Ling, Yu-xiao ; Xu, Biao ; Jiang, Jian-min ; Zhou, Yi-qing ; Luo, Dan ; Zhou, Lin ; Li, Yang ; Chen, Bin ; Chen, Xin-yi ; Ren, Yan-li ; Peng, Ying

OBJECTIVES:

The patient pathway of multidrug-resistant tuberculosis (MDR-TB) in China is an essential but not well-studied area. This study aimed to understand the alignment between patient-initiated care-seeking demands for MDR-TB and the availability of diagnostic and treatment services in Ningbo, a city in eastern China, using patient pathway analysis (PPA).

METHODS:

We collected the diagnostic and treatment data of 240 patients with MDR-TB in Ningbo from 2015 to 2019. Using patient pathway analysis, we matched the medical data of patients from different medical institutions and mapped their care pathways to illustrate their access to medical services.

RESULT:

Our study indicated that the proportion of patients with MDR-TB who chose non-TB-designated medical institutions (55%) was higher than those who chose TB-designated medical institutions (45%) at their initial visit. An estimated 69% of patients with MDR-TB patients received initial TB screening services during their first visit. In this study, 47% of patients needed to visit 4-7 medical institutions to be diagnosed with MDR-TB. Overall, 80% (n = 192) of patients were diagnosed with MDR-TB within four visits, while 13% (n = 30), 4% (n = 10), and 3% (n = 8) of patients were not diagnosed at the fourth visit and remained at level 2, 1, and 0 medical institutions, respectively.

CONCLUSION:

The care-seeking pathway of patients with MDR-TB in Ningbo is complex. This indicates room for improvement in local diagnosis and referral services. There is a need to promote the deployment of MDR-TB screening, diagnosis, and treatment services at lower-level institutions.

2025-12-01·TALANTA

Separation and photostability analysis of retinoic acid isomers and their derivatives based on ion mobility mass spectrometry and theoretical calculations

Article

作者: Wu, Fangling ; Zou, Ying ; Chi, Chaoxian ; Ding, Chuan-Fan

Retinoic acid (RA) regulates cell proliferation, differentiation, and apoptosis and exists in three primary isomers: all-trans-RA (ATRA), 9-cis-RA (9cRA), and 13-cis-RA (13cRA). RA derivatives, such as bexarotene (BT) and arotinoid acid (TTNPB), are used to treat cutaneous T-cell lymphoma and induce cellular pluripotency. Due to their distinct biological activities, accurate identification and analysis of these isomers are crucial. This study developed a rapid and efficient method for analyzing RA isomers and their derivatives using ion mobility mass spectrometry (IM-MS) and theoretical calculations. RA isomers and derivatives exhibit overlapping mobilities and cannot be separated by direct IM-MS. By forming ternary complexes with β-cyclodextrin (β-CD) and metal ions, baseline separation was achieved with a peak resolution (R_p-p) of up to 3.42. Tandem MS and theoretical calculations revealed distinct differences in interactions, spatial structures, and binding energies, enabling mobility-based separation. Photostability tests showed rapid photoisomerization of 13cRA into 9cRA and ATRA within seconds. Analysis of 13cRA soft capsules from four brands demonstrated good stability, with measured content aligning closely with labeled values. This method offers a new approach for accurate RA isomer analysis, with potential applications in pharmaceuticals and food industries.

2025-12-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Oxygen plasma induced MoS2/MoOx heterojunction for high performance SERS application

Article

作者: Wu, Yajian ; Jiang, Tao ; Zeng, Shuwen ; Wen, Wenxi ; Gu, Chenjie ; Zheng, Xinru ; Fan, Weiqi ; Lv, Sheqin ; Chen, Dong

Surface-enhanced Raman scattering (SERS) is a non-destructive spectroscopic analysis technique, and it is known for its high sensitivity and specificity in the detection of trace molecules. In this paper, a novel MoS₂/MoO_x heterostructure based non-metallic SERS substrate for highly sensitive molecule detection was reported. Experimentally, the MoS₂/MoO_x heterojunction was prepared by partially oxidizing the MoS₂ nanosphere into MoO_x in an oxygen plasma environment (O²⁺). It evidenced that the electronic structure and surface properties of the MoS₂/MoO_x heterojunction could be adjusted by precisely controlling the oxidation time, thereby optimizing the SERS performance. The SERS performance of the substrate was evaluated by using the Rhodamine 6G (R6G) molecules as Raman reporters. It showed that a limit of quantification as low as 10^-8 M and an enhancement factor (EF) of 8.54 × 10⁸ (R6G@10^-8 M) could be achieved on the optimal SERS substrate with the set oxidizing time to 300 s. Ultimately, the optimal SERS substrate was employed for detecting bright blue dyes. The results demonstrated that the lowest detectable concentration reaches as low as 10^-6 M, fulfilling the requirements for food safety assessment.

项与宁波大学相关的新闻（医药）

2025-06-14

·今日头条

靶向联合抑制！宁波大学发文：克服肝癌免疫治疗耐药性的新策略

【导读】尽管靶向PD-L1的免疫检查点抑制剂在肝细胞癌（HCC）中显示出临床疗效，但肿瘤细胞常常通过 PD-L1 过度表达来逃避免疫监视，而这种现象的调控机制仍不清楚。 6月7日，宁波大学研究人员在期刊《Cell Death Discovery》上发表了题为“LMNB2-mediated high PD-L1 transcription triggers the immune escape of hepatocellular carcinoma”的研究论文，本研究中，研究人员发现免疫治疗敏感的肝细胞癌（HCC）患者中存在B2（LMNB2）的异常上调。功能表征显示，LMNB2 在与 Jurkat 细胞共培养时作为 PD-L1 的转录调节因子，增强了肝癌细胞的免疫逃逸机制。尤其是，LMNB2 与阿特珠单抗（PD-L1 抑制剂）的联合靶向在体外和体内均显示出抑制肿瘤进展的协同作用，特别是在具有 SPOP 突变或 LMNB2 过表达的肝癌模型中。这些发现揭示了肝细胞癌免疫逃逸中一种新的泛素化依赖性调控轴，并提出了靶向联合抑制策略以克服肝细胞癌免疫治疗耐药性。 https://www-nature-com.libproxy1.nus.edu.sg/articles/s41420-025-02540-7#Abs1 背景知识 01 原发性肝癌主要由肝细胞癌（HCC）和肝内胆管癌（ICC）构成，其中肝细胞癌占 75% 至 85%，肝内胆管癌占 10% 至 15%。在早期至中期阶段，肝细胞癌患者可通过手术切除、肝移植、射频消融或经导管化疗栓塞等手段进行根治性治疗。然而，由于症状出现较晚，大多数患者在确诊时已处于癌症晚期，只能接受全身治疗。近年来，免疫检查点阻断（ICB）疗法取得了重大进展。值得注意的是，诸如抗程序性细胞死亡配体 - 1（PD-L1）抗体之类的免疫检查点抑制剂在肝细胞癌治疗中展现出了显著的临床疗效。尽管免疫疗法在部分肝细胞癌（HCC）患者中取得了显著的临床疗效，但大多数患者对 PD-1/PD-L1 靶向免疫疗法无反应。具体而言，肿瘤细胞通过下调或丢失肿瘤抗原以及降低主要组织相容性复合体（MHC）的表达来逃避免疫识别。它们过度表达诸如 PD-L1 和CTLA4等免疫检查点分子来抑制 T 细胞功能，同时招募调节性 T 细胞（Tregs）和髓源性抑制细胞（MDSCs）等免疫抑制细胞，通过抑制性细胞因子来营造免疫抑制微环境。此外，代谢竞争以及缺氧进一步损害免疫细胞活性。靶向PD-L1/PD-1 的免疫检查点抑制剂可对抗这些机制以恢复抗肿瘤免疫。然而，驱动癌细胞中 PD-L1 异常过度表达的具体基因改变仍知之甚少。 LMNB2 可通过诱导 T 细胞凋亡促进肿瘤生长 02 为了探究 LMNB2 对免疫浸润的影响，研究人员在小鼠肝癌 Hepa1-6 细胞中调控了 LMNB2 的表达，构建了过表达和敲低组。随后将这些细胞注射到 C57BL/6J 小鼠体内，建立皮下肿瘤模型。对肿瘤重量和体积的分析表明，LMNB2 显著促进了肝癌肿瘤的进展。对 T 细胞活化标志物 CD3 和 CD8 的评估显示，LMNB2 过表达组的免疫浸润减少。在 Jurkat 细胞与不同 LMNB2 表达水平的肝癌细胞系（Huh7 和 HepG2）的共培养实验中，研究人员发现 LMNB2 水平升高会显著诱导 T 细胞凋亡和细胞周期停滞。此外，共培养上清液分析表明，高 LMNB2 表达显著降低了炎症细胞因子白细胞介素 -2/4/10（IL-2/4/10）和干扰素 -γ（IFN-γ）的分泌。另外，功能表型检测表明，LMNB2 水平升高促进了体外肝细胞癌的发生和进展。综上所述，这些数据表明，LMNB2 水平升高在体外和体内均促进肿瘤生长。 LMNB2 可通过诱导 T 细胞凋亡来促进肿瘤生长结论 03 总之，SPOP 突变和 SPOP 低表达会增加 LMNB2 的表达，从而提高肝细胞癌（HCC）中 PD-L1 的表达。揭示这些导致 PD-L1 异常表达的遗传机制，可能有助于指导肝细胞癌中 PD-1/PD-L1 阻断免疫疗法的应用。参考资料： https://www-nature-com.libproxy1.nus.edu.sg/articles/s41420-025-02540-7#Abs1 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。责任声明：本稿件如有错误之处，敬请联系转化医学网客服进行修改事宜！微信号：zhuanhuayixue 热门推荐活动点击免费报名 🕓 上海｜2025年6月12-15日 ▶ 第七届上海国际癌症大会暨第十八届全国医学生物技术研讨会暨第六届中德双边论坛 🕓 上海｜2025年7月17-18日 ▶ 第四届长三角体外诊断产业高峰论坛 🕓 北京｜2025年9月19-20日 ▶ 第六届单细胞技术应用研讨会暨空间组学前沿研讨会 🕓 上海｜2025年11月14-15日 ▶ 第二届中国类器官转化医学大会点击对应文字查看详情

免疫疗法

2025-04-23

·PRNewswire

A Breakthrough in Brain Surgery Monitoring: Guarding Lives with Raytron's Thermal Imaging Technology

YANTAI, China, April 23, 2025 /PRNewswire/ -- In high-stakes neurosurgery, gaining real-time insights into cerebral blood flow is vital yet challenging. Conventional indocyanine green (ICG) fluorescence imaging relies on contrast agents and offers limited repeatability. Now, infrared thermography cameras promise a non-contact, contrast-free, radiation-free, and non-invasive diagnostic imaging alternative, delivering continuous monitoring that enhances surgical precision and patient safety. How Infrared Thermal Imaging Empowers Medical Diagnostics Thermal imaging cameras convert subtle temperature variations from cerebral blood circulation into high-resolution thermal maps, enabling surgeons to "see" vascular flow invisible to the naked eye. This non-invasive thermal imaging technology integrates seamlessly into neurosurgical workflow, such as cerebrovascular bypass, offering continuous intraoperative monitoring without interruption. Raytron's Thermographic Imaging Camera for Clinical Application in Neurosurgery Raytron, a prominent global provider of infrared thermal imaging solutions, has developed an innovative thermal camera for medical use. In 2023, a surgical team led by Dr. Lin Jinghui at the First Affiliated Hospital of Ningbo University—a top-tier public hospital in China—deployed Raytron's proprietary ATR1280 thermal imaging camera during life-saving bypass operations for patients with moyamoya disease, a rare cerebrovascular disorder. The team conducted intraoperative infrared imaging on 21 adult patients undergoing STA-MCA (superficial temporal artery to middle cerebral artery) bypass surgery and identified several key advantages over conventional methods: Real-time, high-resolution thermal imaging camera for research Clearer visualization of anastomotic blood flow Seamless integration into the surgical workflow Greater quantitative accuracy in cerebral blood flow monitoring These benefits may support more informed decision-making and contribute to improved patient outcomes, marking a promising development in thermographic neurosurgical imaging. Raytron's Global Vision in Infrared Thermal Imaging: Raytron is a leading high-tech enterprise dedicated to the research and development of ASICs, MEMS sensors, and AI algorithms. With a portfolio of 1,200 patents and an R&D workforce comprising 48% of its over 3,000 employees, Raytron delivers advanced thermal imaging solutions in medical diagnostics, emergency response and 10 other industry sectors worldwide. Committed to advancing intelligent sensing technology solutions, Raytron aims to create incremental value for customers with technological advancements and help people discover the beauty of the world from more dimensions. For Further Information Contact us for medical-use thermal imaging solutions: Raytron Marketing Department E-mail: [email protected] Website: SOURCE Raytron Technology Co., Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-10-06

·今日头条

新肿瘤抑制因子！宁波大学发文：新的肺癌生物标志物和治疗靶点

【导读】非小细胞肺癌(NSCLC)通常在晚期被诊断出来，这限制了治疗干预的有效性。本研究旨在探讨新发现的circLIFRSA在PTEN/AKT信号通路中的作用及其在非小细胞肺癌恶性过程中的作用。 9月28日，宁波大学研究团队在期刊《Molecular Cancer》上发表了题为“CircLIFRSA/miR-1305/PTEN axis attenuates malignant cellular processes in non-small cell lung cancer by regulating AKT phosphorylation”的研究论文，本研究中，研究人员发现circLIFRSA在NSCLC细胞和组织中的表达显著降低。这种下调与各种临床病理特征相关，并表明其作为非小细胞肺癌早期诊断生物标志物的潜力。重要的是，circliffsa在非小细胞肺癌细胞中抑制细胞生长和增殖，同时促进细胞凋亡。这些发现表明circlifsa /miR-1305/PTEN轴通过调节AKT磷酸化来减弱恶性过程，并为circlifsa作为NSCLC早期诊断的生物标志物和有希望的治疗靶点的潜力提供了新的见解。 https://molecular-cancer-biomedcentral-com.libproxy1.nus.edu.sg/articles/10.1186/s12943-024-02120-w#Sec15 背景知识 01 肺癌被认为是全世界癌症相关死亡的主要原因，对男性和女性人口的死亡率都有重大影响。鉴于肺癌在临床和病理特征上的相当多样性，肺癌可大致分为两种主要类型:非小细胞肺癌(NSCLC)和小细胞肺癌(SCLC)。非小细胞肺癌约占所有肺癌病例的85%，是最常见的亚型。尽管近几十年来晚期肺癌的发病率逐渐下降，但早期肺癌诊断率每年增加了4.5%。目前，肺癌患者的3年生存率仍低于35%。肺癌，特别是非小细胞肺癌的发病机制尚不完全清楚。因此，有必要研究促进NSCLC发生和发展的分子机制。这样的研究可能为生物标志物的鉴定和新型治疗剂的开发提供有价值的见解。环状RNA (circRNAs)是一类独特的非编码RNA (ncRNAs)，其特征是共价闭合、连续的环状结构。研究已经确定了与各种癌症类型的发生和发展有关的差异表达的环状RNA。由于其独特的结构特性，circRNAs通常被认为是内源性竞争RNA(ceRNAs)的角色，这是基因表达调控不可或缺的一部分。例如，circPTK2已被证明通过海绵miR-429和miR-200b-3p作为转录中介因子1γ (TIF1γ)的ceRNA，从而抑制TGF-β诱导的非小细胞肺癌上皮-间质转化(EMT)和肿瘤转移。这表明过表达circPTK2可能是晚期NSCLC的一种潜在治疗策略。然而，新发现的环状RNA在非小细胞肺癌中的功能和机制在很大程度上仍未被探索。血源性circLIFRSA可作为肺癌的早期诊断生物标志物 02 为了评估circLIFRSA的诊断性能，研究人员利用RT-qPCR技术量化了其在健康个体（n=49）、良性肺部疾病患者（n=30）和肺癌患者（n=60）的全血样本中的表达水平。健康对照组和良性肺部疾病患者的年龄、性别、BMI（P=0.0965）或吸烟状态（P=0.2839）等人口统计学特征均未显示出显著相关性。研究人员按照既定方法，通过梯度稀释确定RNA浓度和循环阈值（Ct）值，生成标准曲线，以确定全血中circLIFRSA的拷贝数。值得注意的是，在健康个体的全血中检测到circLIFRSA的含量极低。相反，与健康对照组相比，良性肺部疾病患者全血中的circLIFRSA拷贝数略有增加。更重要的是，肺癌患者全血中circLIFRSA的平均拷贝数约为每微升500个。受试者工作特征（ROC）曲线分析表明，circLIFRSA在区分良性肺部疾病与肺癌时的曲线下面积（AUC）值为0.8578（95%置信区间：0.7539-0.9616），敏感性为98.53%，特异性为81.52%。此外，ROC曲线分析显示，circLIFRSA在区分早期I期非小细胞肺癌（NSCLC）与更晚期（II-IV）病变时的AUC值为0.7542（95%置信区间：0.7265-0.9481），敏感性为64%，特异性为82%。因此，circLIFRSA有望成为非小细胞肺癌患者的早期诊断生物标志物。 circLIFRSA可作为肺癌的早期诊断生物标志物 circLIFRSA对NSCLC细胞的恶性进程具有抑制作用 03 鉴于在NSCLC患者中观察到circlirsa和肿瘤大小之间的关联，研究人员假设其在癌细胞生长的调节中发挥作用。为了探索这一假设，研究人员进行了靶向circlirsa的功能获得实验，以评估其对A549细胞生长和增殖的影响。结果表明，在A549细胞中，circlirsa过表达(OE)的效率约为载体对照组的80倍。MTT结果显示，过表达circlirsa显著抑制A549细胞的生长。此外，克隆形成实验表明，circlirsa过表达阻碍了A549细胞克隆的形成。这些结果表明，上调circlirsa有效抑制细胞生长和增殖。关于circlirsa对细胞凋亡和细胞周期进程的影响，研究结果表明，circlirsa过表达增强了A549细胞的凋亡。然而，值得注意的是，在A549细胞中，circlirsa过表达并没有显著影响DNA含量或不同阶段的细胞增殖指数(PI)。因此，虽然circlirsa似乎诱导细胞凋亡，但它似乎不影响NSCLC的细胞周期进展。为了阐明与circlirsa /miR-1305/PTEN轴相关的下游信号级联，研究人员聚焦于PTEN下游的AKT信号效应物。蛋白质免疫印迹分析表明，circlirsa过表达导致PTEN和总AKT (tAKT)的上调，伴随磷酸化AKT (pAKT)的下调。相反，circlirsa敲低导致PTEN水平降低，pAKT水平升高，而tAKT水平无显著变化。值得注意的是，miR-1305模拟物治疗导致PTEN表达降低，同时pAKT水平升高。此外，circlirsa和miR-1305共过表达表明，circlirsa减弱了miR-1305对PTEN表达的抑制作用。综上所述，这些发现表明circlirsa /miR-1305/PTEN轴在AKT磷酸化中发挥调节作用，从而影响恶性细胞过程。研究小结 04 综上所述，本研究确定了circlirsa是一种新型的肿瘤抑制因子，并阐明了其在NSCLC中通过circlirsa /miR-1305/PTEN轴和AKT磷酸化的调节来减弱恶性过程中的作用。此外，circlirsa在外周血中的高表达为NSCLC与良性肺疾病的鉴别诊断提供了潜在的诊断潜力，使其有望成为NSCLC治疗的生物标志物和治疗靶点。【参考资料】 https://molecular-cancer-biomedcentral-com.libproxy1.nus.edu.sg/articles/10.1186/s12943-024-02120-w#Sec15 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。热门推荐活动点击免费报名 🕓 上海｜11月15日-16日 ▶ 2024第一届中国类器官转化医学大会点击对应文字查看详情

临床研究诊断试剂

100 项与宁波大学相关的药物交易

登录后查看更多信息

100 项与宁波大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年06月27日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Flavokawain A ( CDT1 )	急性髓性白血病更多	临床前
AM-04(Ningbo University)	细菌感染更多	临床前
Cucurbitacin IIb	结肠炎更多	临床前
CN118994115 专利挖掘	其他疾病更多	药物发现
CN117344004 ( OXA1L )专利挖掘	血管疾病更多	药物发现